09th week of 2014 patent applcation highlights part 47 |
Patent application number | Title | Published |
20140057910 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2014-02-27 |
20140057911 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS - Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents. | 2014-02-27 |
20140057912 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS - The present invention provides pyrimidine-4,6-diamine derivatives of Formula (I): wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases. | 2014-02-27 |
20140057913 | AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF - Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed. | 2014-02-27 |
20140057914 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases. | 2014-02-27 |
20140057915 | KINASE INHIBITORS - There are provided compounds of formula I, | 2014-02-27 |
20140057916 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY - This invention relates to substituted 4-pyridones of formula 1 | 2014-02-27 |
20140057917 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects - Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed. | 2014-02-27 |
20140057918 | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof - Methods of therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed. | 2014-02-27 |
20140057919 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS - The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections. | 2014-02-27 |
20140057920 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY - This invention relates to substituted 4-pyridones of formula 1 | 2014-02-27 |
20140057921 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES - The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I) wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals in the prevention and treatment of psychotic and neurodegenerative disorders. The claimed compounds act as nicotinic acetylcholine receptors (NACHR) ligands. | 2014-02-27 |
20140057922 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM - A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of allylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride. | 2014-02-27 |
20140057924 | BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed. | 2014-02-27 |
20140057925 | AMORPHOUS FORM OF VILAZODONE HYDROCHLORIDE AND PROCESS FOR ITS PREPARATION - The present invention relates to an amorphous form of vilazodone hydrochloride and process for the preparation of amorphous form of vilazodone hydrochloride. The invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD). | 2014-02-27 |
20140057926 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY - This invention relates to substituted 4-pyridones of formula 1 | 2014-02-27 |
20140057927 | INHIBITORS OF BETA-SECRETASE - The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. | 2014-02-27 |
20140057928 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR - This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: | 2014-02-27 |
20140057929 | BESYLATE SALT OF A BTK INHIBITOR - The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same. | 2014-02-27 |
20140057930 | METHOD OF CONTROLLING NEONICOTINOID RESISTANT HEMIPTERA - The invention relates to a method of controlling insects from the order hemiptera that resistant to neo-nicotinoid insecticides using spiroheterocyclic pyrrolidine dione derivatives. | 2014-02-27 |
20140057931 | BUPRENORPHINE ANALOGS - The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R | 2014-02-27 |
20140057932 | 1,3-Dioxanomorphides and 1,3-Dioxanocodides - The application is directed to compounds of Formula I | 2014-02-27 |
20140057934 | METHYLNALTREXONE NASAL FORMULATIONS, METHODS OF MAKING, AND USE THEREOF - Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications. | 2014-02-27 |
20140057936 | LPA2 Receptor-Specific Benzoic Acid Derivatives - Disclosed are compounds effective for inhibiting cellular apoptosis and for protecting cells and tissues from the apoptotic effects of chemotherapeutic agents and/or ionizing radiation. Compounds of the invention act as agonists of the LPA | 2014-02-27 |
20140057937 | ANTAGONISTS OF CHEMOKINE RECEPTORS - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists. | 2014-02-27 |
20140057938 | KAT ll INHIBITORS - Compounds of Formula I: | 2014-02-27 |
20140057939 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS - The invention provides methods for the treatment of cognitive disorders utilizing specific 5-HT | 2014-02-27 |
20140057940 | Methods for Treating or Preventing Cardiac and Neurological Disorders Using Chemokine Receptor Antagonists - The invention provides methods for treating or preventing cardiac and neurological disorders using chemokine receptor antagonists. | 2014-02-27 |
20140057941 | Methods For Increasing Mean Corpuscular Volume - The invention relates to methods and compounds useful for treating deficiencies in hemoglobin production. Methods and compounds useful for increasing mean corpuscular volume are provided. Methods and compounds for treating microcytosis and methods and compounds for treating microcytic anemia are also provided. | 2014-02-27 |
20140057942 | NOVEL ROCK INHIBITORS - The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, —NH—, or a direct bond; Y is —NH— or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical consisting of a satured (poly)cycle, including fused, bi-, spiro or bridged carbocycles and heterocycles; in particular selected from the group consisting of: Formula (II), Ar is selected from the group comprising: Formula (III), R | 2014-02-27 |
20140057943 | Method of Treating Cancer - This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF. | 2014-02-27 |
20140057944 | 4-[2-(2-FLUOROPHENOXY METHYL)PHENYL]PIPERIDINE COMPOUNDS - The invention relates to compounds of formula I: | 2014-02-27 |
20140057945 | Bis(difluoromethyl)pyrazoles as Fungicides - Bis(difluoromethyl)pyrazole derivatives of the formula (I) | 2014-02-27 |
20140057946 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF - The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia. | 2014-02-27 |
20140057948 | VIF AS A TARGET FOR HIV INHIBITION - The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein. | 2014-02-27 |
20140057949 | Beverage Products - This disclosure provides beverage products comprising a compound of Formula I, such as anatabine, suitable for human consumption. | 2014-02-27 |
20140057950 | DERIVATIVES OF ENGLERIN FOR THE TREATMENT OF CANCER - The present invention relates to compounds of the general formula (I) | 2014-02-27 |
20140057951 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE - The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders. | 2014-02-27 |
20140057952 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-02-27 |
20140057953 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS - The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 2 (l7beta-HSD2) inhibitors of formula (I), their production and use, notably for the treatment and prophylaxis of sex steroid deficient diseases like osteoporosis in men and women. | 2014-02-27 |
20140057954 | CHEMICAL COMPOSITION - The present invention is directed to stable chemical compositions and dosage forms that comprise nebivolol and valsartan and which achieve therapeutically effective plasma levels of both actives in hypertensive patients following administration, as well as to methods of lowering blood pressure and treating hypertension using such compositions and dosage forms. | 2014-02-27 |
20140057955 | NOVEL, PROTECTIVE, ANTI-INFLAMMATORY RECEPTOR AND ITS USE IN PRESERVATION OF MITOCHONDRIAL FUNCTION, WOUND HEALING AND REPAIR - Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 AT | 2014-02-27 |
20140057956 | COPOLYMERISED FATTY BODY, PREPARATION METHOD THEREOF AND USES OF SAME - The invention relates to a copolymer having a backbone that is obtained by radical polymerisation of: a fatty body (A) comprising unsaturations and/or hydroxyl functions; and at least one monomer (B) including at least one function that can be polymerised by means of radical polymerisation and comprising either (i) at least one linear or branched alkyl chain having preferably between 16 and 44 carbon atoms, and more preferably at least 18 carbon atoms, e.g. at least 20 carbon atoms, in particular 22 carbon atoms or 44 carbon atoms, or (ii) a reactive function. The invention also relates to a method for modifying the rheological properties of an non-aqueous medium with the addition of a copolymer of the invention. The invention further relates to a composition formed totally or partially by a copolymer of the invention. Preferably, the composition is an emulsifiable composition. Furthermore, the invention relates to a composition comprising a copolymer of the invention and an emulsifying agent. | 2014-02-27 |
20140057957 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase - The present invention is directed to novel thiophene inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2014-02-27 |
20140057958 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES - The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2014-02-27 |
20140057959 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE - The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. | 2014-02-27 |
20140057960 | NOVEL REPRESSOR ON IFN-LAMBDA PROMOTER AND SIRNA AGAINST ZEB1 AND BLIMP-1 TO INCREASE IFN-LAMBDA GENE ACTIVITY - The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases. | 2014-02-27 |
20140057961 | SIN3B COMPLEX INHIBITION AND USE THEREOF IN THE PREVENTION OF PRO-ONCOGENIC INFLAMMATION AND CANCER - Methods for inactivating Sin3B and its associated activities to prevent, inhibit or attenuate pro-oncogenic inflammation and cancer progression, in particular pancreatic cancer progression are provided. | 2014-02-27 |
20140057962 | Compositions and Methods for the Treatment of Cancer - Compositions and methods for treating, detecting, and diagnosing cancer are disclosed. | 2014-02-27 |
20140057963 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. | 2014-02-27 |
20140057964 | Oligomers - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 2014-02-27 |
20140057965 | dsRNA For Treating Viral Infection - The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells. | 2014-02-27 |
20140057966 | METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS - Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11 | 2014-02-27 |
20140057967 | METHOD OF SCREENING FOR CHAPERONIN MODULATOR - The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate. | 2014-02-27 |
20140057968 | Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease - Methods and compositions are disclosed for controlling expression of TNF receptors (TNFR1 and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-α activity or activity of the relevant ligand. Reducing TNF-α activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-α activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H. | 2014-02-27 |
20140057969 | Oncovector Nucleic Acid Molecules and Methods of Use - Provided herein are non-viral nucleic acid vectors, including non-viral oncovectors, that are autonomously replicating plasmids (ARPs). The non-viral nucleic acid vectors exhibit fusogenic activity and can exhibit other anti-tumor or cytotoxic activities. Also provided herein are methods and uses of the non-viral nucleic acid vectors for treating cancer. | 2014-02-27 |
20140057970 | Use of Hepcidin Binding Nucleic Acids for Depletion of Hepcidin From the Body - The present invention is related to a method for reducing the level of hepcidin in a body fluid from a subject, comprising
| 2014-02-27 |
20140057971 | LaFORA'S DISEASE GENE - A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease. | 2014-02-27 |
20140057972 | ANTIBODY AGAINST THE CSF-1R - The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions. | 2014-02-27 |
20140057973 | PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING DISEASES RELATED TO JOINT AND CONNECTIVE TISSUE - The present invention relates to a pharmaceutical composition for preventing and treating joint-related disease and connective tissue-related disease, the composition comprising two or more selected from the group consisting of polyol, amino acid, ornithine, nucleic acid and vitamin C. The pharmaceutical composition prevents and treats new arthritis, joint damage and connective-related diseases in an effective and economical manner without concerns about side effects, complications and like. | 2014-02-27 |
20140057974 | METHODS FOR THERAPY OF NEURODEGENERATIVE DISEASE OF THE BRAIN - A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic factor), into a targeted region of the brain (such as the substantia nigra) using a lentiviral expression vector. The neurotrophin is delivered to, or within close proximity of, identified defective, diseased or damaged brain cells. The concentration of neurotrophin delivered as part of a neurotrophic composition varies from 10 | 2014-02-27 |
20140057975 | REDUCED CENTRAL CORNEAL THICKENING BY USE OF HYDROPHILIC ESTER PRODRUGS OF BETA-CHLOROCYCLOPENTANES - Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided. | 2014-02-27 |
20140057976 | USNIC ACID TOPICAL FORMULATION - Topical skin treatment formulation containing usnic acid or an usnate salt, dissolved in a solvent system comprising (i) dimethyl isosorbide; (ii) a C1 to C9 alkyl salicylate; and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of microbial conditions, in particular acne. The solvent system assists in the effective dissolution of the usnic acid or usnate and in targeting its delivery to relevant sites on the skin. | 2014-02-27 |
20140057977 | Induction of Arteriogenesis - The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition. | 2014-02-27 |
20140057978 | NOVEL USE OF BENZOFURANYLSULFONATES - Provided herein are compounds for use in the treatment of central nervous system (CNS)-trauma related disorders like spinal cord injuries. Pharmaceutical compositions, single unit dosage forms, and kit suitable for use for the treatment of (CNS)-trauma related disorders are also disclosed. | 2014-02-27 |
20140057979 | Expression Modulator For Clock Gene - The present invention provides substances that can be used in a broad range of applications and effectively regulate clock gene expression. | 2014-02-27 |
20140057980 | CALCILYTIC COMPOUNDS - Novel calcilytic compounds and methods of using them are provided. | 2014-02-27 |
20140057981 | SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID - This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug. | 2014-02-27 |
20140057982 | RETINOIDS AND USE THEREOF - The present invention provides new retinoid compounds and uses of the compounds in humans and animals for non-neoplastic dermal or inflammatory conditions or disorders. | 2014-02-27 |
20140057983 | EYE DROPS FOR TREATMENT OF CONJUNCTIVOCHALASIS - An ophthalmic preparation and method, usable to treat conjunctivochalasis. The ophthalmic preparation comprises an aqueous solution of glycerol. The preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances. The method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient. | 2014-02-27 |
20140057984 | METHODS OF TREATING CORTICOBASAL DEGENERATION COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. Patients diagnosed with, or at risk for, certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, corticobasal degeneration, Wilson's disease or stroke or those patients having head or spinal cord injury. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). | 2014-02-27 |
20140057985 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF - The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia. | 2014-02-27 |
20140057986 | GENE AND GENE EXPRESSED PROTEIN TARGETS DEPICTING BIOMARKER PATTERNS AND SIGNATURE SETS BY TUMOR TYPE - Provided herein are methods and systems for identifying a therapeutic for an individual, such as a therapeutic not previously identified for treating the individual. The therapeutic can be identified by molecular profiling, such as determining the biomarker patterns or signature sets of a biological sample of an individual. | 2014-02-27 |
20140057987 | Disinfectant Spray with Indicator - Compositions are provided that comprise a disinfectant, a pH indicator dye, and an alkaline substance. The pH indicator dye expresses a color when initially sprayed, but loses or changes color once sprayed. The compositions may be used to disinfect surfaces, and the pH indicator dye indicates what surface has been disinfected and ensures that a sufficient period of time has passed to disinfect the surface. Dispensing systems that are not fully air tight are provided for containing and dispensing the composition. | 2014-02-27 |
20140057988 | ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE - A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults. | 2014-02-27 |
20140057989 | POLYAMINE TRANSPORTER SELECTIVE COMPOUNDS AS ANTI CANCER AGENTS - Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters. | 2014-02-27 |
20140057990 | PREPARATION OF CHIRAL AMIDES AND AMINES - This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure. | 2014-02-27 |
20140057991 | Cosmetic composition comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone - The invention relates to a composition comprising, in a physiologically acceptable aqueous medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<δ, <30 and 15<δ | 2014-02-27 |
20140057992 | CONTROLLED ACTIVATION OF THE REUTERIN-PRODUCTION MACHINERY OF LACTOBACILLUS - Methods for the controlled activation of the reuterin-production machinery of | 2014-02-27 |
20140057993 | Prophylaxis and Treatment of Enteropathogenic Bacterial Infection - In accordance with the present invention, methods are provided for the prevention and/or treatment of enteropathogenic bacterial infection in the gastrointestinal tract of a subject, and the diarrhea associated with the infection, by administration to the subject of a low molecular weight polyethylene glycol, as well concurrent administration with other antibiotic and antidiarrheal agents. Methods for reduction or suppression of inflammation, and inhibition of β1-integrin expression in the gastrointestinal mucosa are also provided. Also described is a kit suitable for use with the methods disclosed. | 2014-02-27 |
20140057994 | COMPOSITIONS COMPRISING SUBSTITUTED PHENOLS AND TOPICAL APPLICATION THEREOF - The present invention relates to compositions comprising substituted phenols, and methods of treating human skin and signs of skin aging using said compositions. | 2014-02-27 |
20140057995 | AQUEOUS-LIPIDIC CAROTENOID-CONTAINING COMPOSITIONS - The invention provides a primary carotenoid-containing composition comprising an aqua-containing component, a lipid-containing component and a carotenoid-containing fiber material from plant origin with lowered content of aqua-soluble substances. The invention also provides oral compositions that comprise the primary composition in a foodstuff, in a food supplement or in a pharmaceutical preparation. | 2014-02-27 |
20140057996 | METHOD FOR PREPARING SILICA COMPOSITIONS, SILICA COMPOSITIONS AND USES THEREOF - A method for producing a flowing silica composition including a sol-gel transfer, where redispersion is carried out. The redispersion includes adding, after having reached gel point of the sol-gel transfer, liquid into the gel formed by the sol-gel transfer, and the addition being made within a sufficiently short time period after reaching the gel point, to result, after mixing of the gel and the liquid, in a rheologically homogenous flowing silica composition, which is and remains injectable as such, or by short stirring <30 s, through a thin 22G needle. Also disclosed are flowing silica compositions and gels obtainable by methods of the invention, and uses of flowing silica compositions. | 2014-02-27 |
20140057997 | COSMETIC COMPOSITION COMPRISING 4-(3-ETHOXY-4-HYDROXYPHENYL)-2-BUTANONE AND A LIPOPHILIC SOLVENT - The invention relates to a composition comprising, in a physiologically acceptable oily medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<δ | 2014-02-27 |
20140057998 | USE OF HIGHLY-BRANCHED POLYCARBONATES IN COSMETIC AND DERMATOLOGICAL FORMULATIONS - The present invention relates to compositions which comprise highly-branched polycarbonates, to the use of these highly-branched polycarbonates in cosmetics and dermatology and to substituted highly-branched polycarbonates. | 2014-02-27 |
20140057999 | PROTECTIVE, HYDROCOLLOID FOR ACTIVE INGREDIENTS - (Modified) rice endosperm protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) rice endosperm protein and at least one active ingredient and to their manufacture, as well as to the (modified) rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) rice endosperm protein and such a composition, respectively. | 2014-02-27 |
20140058000 | DIAGNOSTIC MARKERS FOR DETERMINING THE PREDISPOSITION TO THE DEVELOPMENT OF CERVICAL CANCER AND OLIGONUCLEOTIDES USED FOR THE DETERMINATION - The present invention relates to a method for predisposition prediction of a subject to the development of cervical cancer and/or cancer precursors in an infection with the human papilloma virus (HPV) and/or for the detection of a persistent HPV infection, the method comprising the steps of obtaining a sample from the subject; and detecting at least one of the diagnostic markers or fragments thereof listed in Table 1 in the sample obtained from the subject. | 2014-02-27 |
20140058001 | Natural Gas to Liquid Fuels - A method and apparatus for converting natural gas from a source, such as a wellhead, pipeline, or a storage facility, into hydrocarbon liquid stable at room temperature, comprising a skid or trailer mounted portable gas to liquids reactor. The reactor includes a preprocessor which desulfurizes and dehydrates the natural gas, a first stage reactor which transforms the preprocessed natural gas into synthesis gas, and a liquid production unit using a Fischer-Tropsch or similar polymerization process. The hydrocarbon liquid may be stored in a portable tank for later transportation or further processed on site. | 2014-02-27 |
20140058002 | Process for Improving the Hydrogen Content of a Synthesis Gas - A process for improving the hydrogen content of a synthesis gas stream to a synthesis loop, comprising the steps of: (a)removing a purge stream comprising hydrogen and hydrocarbons from a synthesis loop; (b)separating hydrogen from the purge stream; (c)passing the purge stream to a reformer and reacting with steam and oxygen to produce a stream comprising hydrogen and carbon monoxide; (d)subjecting the reformed reaction product stream to a shift reaction to produce a stream comprising carbon dioxide and hydrogen; (e)subjecting the product stream from the shift reaction to separation to separate hydrogen from carbon dioxide; (f)supplying the separated hydrogen to the synthesis loop; and (g)removing the carbon dioxide. | 2014-02-27 |
20140058003 | POLYMERIC FOAMS INCLUDING FLUORINATED OXIRANES, METHODS OF PREPARATION, AND USE OF SAME - Foamable compositions are provided that include at least one blowing agent, at least one foamable polymer or a precursor composition thereof, and a nucleating agent. The nucleating agent includes a fluorinated oxirane which, in some embodiments, can have up to a maximum of three hydrogen atoms. The fluorinated oxiranes can have a total of from about 2 to about 12 carbon atoms. Also provided is a process for preparing a polymeric foam and a composition that includes a blowing agent and a nucleating agent comprising a fluorinated oxirane. | 2014-02-27 |
20140058004 | USE OF METAL SALTS OF A CARBOXYLIC ACID IN THE PRODUCTION OF POLYURETHANE SYSTEMS - A catalyst system which is suitable for catalyzing the production of polyurethane systems is provided. The catalyst system contains a metal salt of a carboxylic acid to whose carbonyl carbon a hydrogen atom or a hydrocarbon radical is bound, with the proviso that the carboxylic acid does not have exclusively a single ethyl or n-propyl branch in the 2 position. | 2014-02-27 |
20140058005 | THERMOFORMABLE RIGID POLYURETHANE-POLYAMIDE FOAM - The present invention relates to a process for producing a thermoformable rigid polyurethane-polyamide foam having a closed-cell content of less than 70%, which comprises mixing (a) an organic polyisocyanate with (b) one or more polymeric compounds having two or more isocyanate-reactive hydrogen atoms, (c) optionally crosslinking and/or chain-extending agents, (d) one or more carboxylic acids having a functionality of 2 or more, (e) a catalyst comprising a Lewis base component, and (f) optionally auxiliaries and additives to form a reaction mixture and reacting this reaction mixture to form the rigid polyurethane-polyamide foam. The present invention further relates to a thermoformable rigid polyurethane-polyamide foam obtained by such a process and also to the use of such a thermoformable rigid polyurethane-polyamide foam for interior lining or engine compartment lining of motor vehicles. | 2014-02-27 |
20140058006 | FIRE-RESISTANT POLYURETHANE FOAM - A fire-resistant polyurethane foam is provided. A hydroxyl-containing inorganic fire retardant is premixed with a polyisocyanate and a polyol, respectively, to form two premixtures. Then, the two premixtures are mixed for reaction to form a fire-resistant polyurethane foam. Preferably, a combination of different particle sizes of the fire retardant is employed to maximize the amount of the fire retardant and increase the fire resistance of the foam. | 2014-02-27 |
20140058007 | MELT PROCESSABLE POLY(VINYL ALCOHOL) BLENDS AND POLY(VINYL ALCOHOL) BASED MEMBRANES - Technologies and implementations for providing melt processable poly(vinyl alcohol) blends and poly(vinyl alcohol) based membranes are generally disclosed. | 2014-02-27 |
20140058008 | Ocular Lens - A method of making an ocular lens device (and resulting lens device) from a polyolefin copolymer material having a crosslinking component, wherein the material is processed to remove unwanted reaction byproducts that can contribute to reduced transparency of the polyolefin copolymer material in the ocular environment of the eye. | 2014-02-27 |
20140058009 | PVA-PAA Hydrogels - The invention provides fabricated PVA-hydrogels, PVA-hydrogel-containing compositions, and methods of making the same. The invention also provides methods of implanting or administering the PVA-hydrogels, or the PVA-hydrogel-containing compositions to treat a subject in need. Methods of cross-linking pre-solidified or pre-gelled hydrogel particles and making cross-linked PVA-hydrogels, and cross-linked PVA-hydrogel-containing compositions also are disclosed herein. | 2014-02-27 |
20140058010 | LASER CURABLE POLYMERISABLE COMPOSITION FOR THE PROTECTION OF HARD TISSUE - One-component heat-curable sealant composition for the protection of exposed dental surfaces, comprising
| 2014-02-27 |
20140058011 | ANTIFOULING COMPOSITION - The present invention relates to the use of polyoxalates as binders for antifouling coating compositions and antifouling coating compositions comprising the polyoxalates. | 2014-02-27 |
20140058012 | Aqueous Epoxy and Organo-Substituted Branched Organopolysiloxane Emulsions - Aqueous emulsions of epoxy- and organo-substituted, branched organopolysiloxanes are prepared by emulsifying the latter in water with the aid of a dispersing agent. The emulsions are storage stable and are useful in multi-component coating, adhesive, and binder systems. | 2014-02-27 |
20140058013 | COMPOSITE MATERIAL WITH POLYAMIDE PARTICLES - Pre-impregnated composite material (prepreg) is provided that can be cured/molded to form composite parts having high compression strength under hot and wet conditions, as well as, high damage tolerance and interlaminar fracture toughness. The matrix resin includes a thermoplastic particle component that includes polyamide particles which are composed of the polymeric condensation product of a methyl derivative of bis(4-aminocyclohexyl)methane and an aliphatic dicarboxylic acid. | 2014-02-27 |